Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E”

135 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 135 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Early research (Phase 1)UnknownNCT05019534
What this trial is testing

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
West China Hospital 12
Testing effectiveness (Phase 2)Study completedNCT05510895
What this trial is testing

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Who this might be right for
Colorectal CancerColon CancerBRAF V600E+2 more
AIO-Studien-gGmbH 2
Testing effectiveness (Phase 2)Looking for participantsNCT06763029
What this trial is testing

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Fudan University 36
Testing effectiveness (Phase 2)Looking for participantsNCT06978400
What this trial is testing

Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Who this might be right for
Neoplasms
Blokhin's Russian Cancer Research Center 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT03839342
What this trial is testing

Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Who this might be right for
Solid Tumor
University Health Network, Toronto 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526782
What this trial is testing

ENCOrafenib With Binimetinib in bRAF NSCLC

Who this might be right for
Non Small Cell Lung CancerBRAF V600E
Intergroupe Francophone de Cancerologie Thoracique 119
Testing effectiveness (Phase 2)Study completedNCT04790448
What this trial is testing

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 37
Not applicableStudy completedNCT04961619
What this trial is testing

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Who this might be right for
Melanoma
Novartis Pharmaceuticals 39
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Testing effectiveness (Phase 2)Ended earlyNCT04534283
What this trial is testing

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Who this might be right for
CancerCancer MetastaticBRAF V600E+4 more
Anita Turk 16
Large-scale testing (Phase 3)Looking for participantsNCT06008119
What this trial is testing

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc. 165
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Not applicableNot Yet RecruitingNCT05988697
What this trial is testing

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Who this might be right for
NSCLCBRAF V600E MutationAdvanced Cancer+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 36
Not applicableStudy completedNCT04718038
What this trial is testing

Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

Who this might be right for
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Henan Cancer Hospital 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04607421
What this trial is testing

Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Who this might be right for
Neoplasms
Pfizer 841
Testing effectiveness (Phase 2)Ended earlyNCT04390243
What this trial is testing

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Who this might be right for
Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaRecurrent Pancreatic Carcinoma+2 more
Academic and Community Cancer Research United 6
Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Early research (Phase 1)Ended earlyNCT05743036
What this trial is testing

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178717
What this trial is testing

Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

Who this might be right for
Colo-rectal Cancer
Vall d'Hebron Institute of Oncology 25
Next Page